It's pointed out that genetic variability in AMP metabolism may be clinically appropriate as a result of highly polymorphic nature of CYP2D6. In idea, CYP2D6 very poor metabolizers may very well be predicted to need scaled-down doses of AMP and/or be a lot more vulnerable to adverse effects from schedule clinical doses, although CYP2D6 ultra-immedi